AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
IRVINE, Calif., Aug. 30, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq:SVA). Investors who purchased or otherwise acquired Sinovac shares from April 30, 2013 through May 16, 2017, inclusive (the “Class Period”), should contact the firm by September 1, 2017, the lead plaintiff motion deadline.
If you purchased shares of Sinovac during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that such conduct would subject it to heightened regulatory scrutiny; and that as a result, Sinovac’s public statements were materially false and misleading at all relevant times. When this information reached the public, Sinovac’s stock price fell materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
